Page 3 - Binghe Xu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Trastuzumab Deruxtecan Approved in China for HER2-Low Metastatic Breast Cancer

China’s National Medical Products Administration has approved trastuzumab deruxtecan monotherapy in adult patients with unresectable or metastatic HER2-low breast cancer who have previously received a systemic therapy in the metastatic setting or whose disease recurred during or within 6 months of adjuvant chemotherapy.

Binghe xuDaiichi sankyoChina national medical products administrationUnion medical collegeNational clinical research centerNational medical products administrationNew anticancer drugsMedical oncologyCancer hospital chinese academyMedical sciencesPeking union medical collegeNational medical products administration of chinaTrastuzumab deruxtecanUnresectable or metastatic her2 low breast cancer

Genor Biopharma : The latest research data of Lerociclib(GB491) was selected by ASCO Daily News Column, Genor Biopharma s CDK4/6 inhibitor recognized at globe

29 May, 2023 The latest research data of Lerociclib was selected by ASCO Daily News Column, Genor Biopharma s CDK4/6 inhibitor recognized at globe . | May 30, 2023

United statesBinghe xuGenor biopharmaChinese academy of medical sciencesDrug administrationChinese academy of engineeringNews columnFulvestrant may reduce riskDisease progressionNegative breastChinese academyMedical oncologyCancer hospitalBreast cancerJust clinical efficacyMore tolerable

AstraZeneca (AZN) Announces Enhertu Approved in China for Additional HER2-positive Breast Cancer Indication

AstraZeneca (AZN) Announces Enhertu Approved in China for Additional HER2-positive Breast Cancer Indication
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDave fredricksonBinghe xuDaiichi sankyo enhertuDaiichi sankyoKiminori nagaoDepartment of medical oncologyChina national medical products administrationChinese academy of medical sciencesInstitute cancer hospitalNational medical products administrationMedical oncologyCancer hospitalChinese academyMedical sciencesExecutive vice president

Combination Trials Point to New Potential Treatment Strategies in Breast Cancer

Positive trial results for multidrug combinations open up potential new treatment regimens for certain breast cancers.

Soult ukpyolsiSouth koreaFrance generalBinghe xuGenentech perjetaGustave roussyEli lilly verzenioFabrice andrBae kimUnion medical collegeAsan medical centerEuropean society for medical oncology congressDrug administrationEuropean societyMedical oncology congressEli lilly

Frontline Dalpiciclib Improves PFS in HR+/HER2- Advanced Breast Cancer

Dalpiciclib can prolong progression-free survival when added to letrozole or anastrozole in patients with HR+, HER2- advanced breast cancer.

Binghe xuUnion medical collegeChinese academy of medical sciencesChinese academyMedical sciencesPeking union medical college